The moderate increase in inflation in the United States consolidated the expectation of interest rate cuts in December. According to the data released by the US Department of Labor on December 11, local time, the US consumer price index (CPI) increased by 0.3% in November, an increase of 0.1 percentage point over October. Inflation continues to rise moderately, which is in line with the market's previous judgment and also supports the expectation that the Fed will continue to cut interest rates this month. However, considering the slowdown in inflation and the increase in uncertainties affecting the economy, many analysts believe that the Fed may slow down the pace of interest rate cuts in the future. (Economic Information Daily)Japanese and Korean stock markets opened lower, with the Nikkei 225 index down 0.56% at 39,624.05. South Korea's KOSPI index opened down 0.3% to 2,473.75 points.Bank of Japan: The index of small non-manufacturers rose for the second consecutive quarter, reaching the highest level since August 1991.
The Military Orchestra of the People's Liberation Army will go to Vietnam to participate in the celebration. Today, Senior Colonel Wu Qian, director of the Information Bureau of the Ministry of National Defense and spokesman of the Ministry of National Defense, released a message on the recent military-related issues: At the invitation of the Ministry of National Defense of Vietnam, the Military Orchestra of the People's Liberation Army of China will send a team to perform in Vietnam from December 14 to 23 to participate in the celebration of the 80th anniversary of the founding of the Vietnamese People's Army. This move will help deepen the traditional friendship between the Chinese and Vietnamese armed forces and expand the cultural exchanges between the two armed forces. (CCTV military)Onlikon: Compound α-keto acid tablets are planned to be selected for the tenth batch of national centralized drug procurement. Onlikon announced on December 13, and on December 12, the company participated in the bidding for the tenth batch of national centralized drug procurement organized by the National Drug Joint Procurement Office. After the bid opening and evaluation by the Joint Procurement Office, the company plans to select this centralized drug procurement. The indication of that medicine is to prevent and treat the damage caused by metabolic disorder in protein due to chronic renal insufficiency. The drug is a national medical insurance catalogue product, with an annual sales of 218,900 yuan in 2023, accounting for 0.01% of the company's annual operating income in 2023.Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.
Citic Jiantou Pharmaceutical's 2025 strategy: looking for new additions and integration opportunities. Citic Jiantou said that looking forward to 2025, the reform policy in the medical field has been normalized, and the most noteworthy incremental policy in the medical insurance field is to establish a diversified payment system. The medical field is about to usher in the reform of "deep water areas" such as salary system and graded diagnosis and treatment, which is in line with expectations as a whole. At the same time, the innovation of China's pharmaceutical industry has gradually stepped onto the international stage, some sub-sectors will be marginally improved, and industry integration will begin. We are optimistic about the investment opportunities in the pharmaceutical industry in 2025. It is suggested to focus on the new increase (innovation, going out to sea, marginal change) and industry integration opportunities.Britain's GFK consumer confidence index was negative 17 in December, the highest since August, and negative 18 in November. The survey estimated that it was negative 18.A spokesman for UnitedHealth Group said that the mother of Mangione, a suspect accused of shooting a company executive, also had no insurance for UnitedHealth.
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13
Strategy guide 12-13